Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain

Villavicencio, Alicia; Solans, Marta; Auñon-Sanz, Carmen; Roncero, Josep María; Marcos‐Gragera, Rafael

doi:10.1016/j.canep.2020.101841

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased survival in patients with myeloma is probably largely due to changes in the therapeutic arsenal in the last decade [43]. For non-Hodgkin lymphoma and some leukemias, advances in molecular biology and cytogenetic techniques have led to better diagnostic and therapeutic approaches that may be reflected in the observed improved survival [44,45]. Despite the aforementioned advances, no increased survival was observed for chronic lymphoid leukemia, but this may be at least partially due to a bias resulting from the change of diagnostic criteria in the 2008 WHO classification [46].…”

Section: Discussionmentioning

confidence: 99%

Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)

Guevara

Molinuevo

Salmerón

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

The assessment of cancer survival at the population level is essential for monitoring progress in cancer control. We aimed to assess cancer survival and its trends in adults in Spain. Individual records of 601,250 adults with primary cancer diagnosed during 2002–2013 and followed up to 2015 were included from 13 population-based cancer registries. We estimated net survival up to five years after diagnosis and analyzed absolute changes between 2002–2007 and 2008–2013. Estimates were age-standardized. Analyses were performed for 29 cancer groups, by age and sex. Overall, age-standardized five-year net survival was higher in women (61.7%, 95% CI 61.4–62.1%) than in men (55.3%, 95% CI 55.0–55.6%), and ranged by cancer from 7.2% (pancreas) to 89.6% (prostate) in men, and from 10.0% (pancreas) to 93.1% (thyroid) in women in the last period. Survival declined with age, showing different patterns by cancer. Between both periods, age-standardized five-year net survival increased overall by 3.3% (95% CI 3.0–3.7%) in men and 2.5% (95% CI 2.0–3.0%) in women, and for most cancer groups. Improvements were greater in patients younger than 75 years than in older patients. Chronic myeloid leukemia and myeloma showed the largest increases. Among the most common malignancies, the greatest absolute increases in survival were observed for colon (5.0%, 95% CI 4.0–6.0%) and rectal cancers (4.5%, 95% CI 3.2–5.9%). Survival improved even for some cancers with poor prognosis (pancreas, esophagus, lung, liver, and brain cancer). Further investigation of possible sociodemographic inequalities is warranted. This study contributes to the evaluation of cancer control and health services’ effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)

Guevara

Molinuevo

Salmerón

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…2,3,6,11,12 It is estimated that the observed 5-year survival is > 70% and the net survival is between 76% and 91%, depending on the region. 1,[6][7][8]12,15,16 The etiologic factors of MZL differ according to subgroup; in addition, in the case of MALT lymphomas, they also vary with the anatomical location of the tumor. Specifically, MALT-type MZLs are associated with a persistent immune response and have therefore been associated with autoimmune diseases or microbial infections, such as Sjögren's syndrome when localized in the salivary glands, Hashimoto's thyroiditis in thyroid lymphoma, Helicobacter pylori (HP) gastritis in gastric lymphoma, Chlamydia psittaci in lymphomas located in the ocular adnexa, Campylobacter jejuni in intestinal lymphoma, or Borrelia burgdorferi in the skin.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, an increase in incidence has been observed in recent years both in overall MZLs and in the different subgroups 2,3,6,11,12 . It is estimated that the observed 5‐year survival is > 70% and the net survival is between 76% and 91%, depending on the region 1,6–8,12,15,16 …”

Section: Introductionmentioning

confidence: 99%

“…Marginal zone lymphomas (MZLs) are indolent type B non-Hodgkin lymphoid neoplasms with a relatively good prognosis. 1 These types of neoplasms represent around 3% of all lymphoid neoplasms. 2,3 According to the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue tumors, MZLs are classified into three large groups: splenic marginal zone lymphoma (SMZL), nodal marginal zone lymphoma (NMZL), and extranodal MZL, otherwise known as MALT (mucosa-associated lymphoid tissue) lymphomas.…”

Section: Introductionmentioning

confidence: 99%

“…Marginal zone lymphomas (MZLs) are indolent type B non‐Hodgkin lymphoid neoplasms with a relatively good prognosis. 1 These types of neoplasms represent around 3% of all lymphoid neoplasms. 2 , 3 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)

et al. 2023

Self Cite

View full text Add to dashboard Cite

Objective To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs. Methods Population‐based study of MZL collected in the Girona Cancer Registry, 1994–2018. Sociodemographic data, tumor location, and stage were obtained from clinical records. Crude (CR) and age‐adjusted (ASRE) incidence rates expressed per 100,000 person‐years (p‐y) were calculated. Joinpoint regression models were used for the trend analysis according to the MZL group. Five‐year observed and net survival were analyzed. Results A total of 472 MZLs were included, 44 (9.3%) were nodal, 288 (61.0%) extranodal, 122 (25.9%) splenic, and the rest (n = 18) MZL, NOS. The CR for the MZL was 2.89 × 100,000 p‐y (95% CI: 2.63–3.15), the ASRE was 3.26 × 100,000 p‐y (95% CI: 2.97–3.57), and the annual percentage change (APC) was 1.6 (95% CI: 0.5–2.7). The ASRE for nodal MZL was 0.30 × 100,000 p‐y (95% CI: 0.22–0.41) and showed an APC of 2.9% (95% CI: −16.4–26.6). For extranodal MZL, the ASRE was 1.98 × 100,000 p‐y (95% CI: 1.76–2.23) and the APC was −0.4 (95% CI: −2.0–1.2). The most frequent locations of this type of MZL were the gastric (35.4%), skin (13.2%), and respiratory system (11.8%). The ASRE of the splenic MZL was 0.85 (95% CI: 0.71–1.02) with an APC of 12.8 (95% CI: 2.5–24.0). The 5‐year net survival of MZL was 82.1% (95% CI: 76.3–86.5). Conclusions This study reveals differences in the incidence and trend of the incidence of MZL according to the subgroup, showing a significant increase in the overall MZL mainly due to splenic MZL type.

show abstract

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

et al. 2021

View full text Add to dashboard Cite

Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain

Cited by 9 publications

References 20 publications

Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)

Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

Contact Info

Product

Resources

About